Xtant Medical (NYSEAMERICAN:XTNT) raised its full-year 2026 revenue guidance after announcing a distribution agreement that moves the company into the hemostatic agent market, while first-quarter revenue declined from the prior-year period following divestitures and the loss of certain license revenue.
President and Chief Executive Officer Sean Browne said on the company’s first-quarter earnings call that Xtant now expects 2026 revenue of $101 million to $105 million. He attributed the higher outlook to the addition of HEMOBLAST Bellows through a Dilon Technologies agreement and growth in the company’s base business.
